Guardant Health and OncoMed Pharmaceuticals will collaborate using Guardant Health’s digital sequencing technology to develop a custom blood test that looks for specific biomarkers relevant to OncoMed’s ongoing phase Ia/Ib trial of its anti-RSP03 antibody. RSPO3 gene overexpression, including RSPO3 gene fusions, appear to drive tumor growth in subsets of several cancers, including colon, ovarian,...
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
